



February 2, 2021

BY E-MAIL

Canadian Securities Exchange  
100 King Street West, Suite 7210  
Toronto, Ontario M5X 1E1

Dear Sirs/Mesdames:

Re: PharmaDrug Inc. acquisition of Saiiryo Therapeutics Inc.

PharmaDrug Inc. ("PharmaDrug") hereby confirms the closing of the purchase of all of the issued and outstanding shares in the capital of Saiiryo Therapeutics Inc. (the "Transaction"). The Form 9 for the Transaction was filed on January 26, 2021 and there were no changes to the information contained therein.

Pursuant to Section 3.3(a) of CSE Policy 6, Pharmadrug hereby confirms its receipt of all of the issued and outstanding shares of Saiiryo Therapeutics Inc. and the transfer to Pharmadrug of the title thereto.

Yours truly,

(signed) "Daniel Cohen"

Daniel Cohen  
President and CEO